Top searches

PL

Resources

B2RLaw advises biotech company Ambulero on fundraising

27/01/2021

B2RLaw has advised Ambulero, Inc., a biotechnology company developing cell and gene therapy treatments for patients suffering from vascular disease on funding of up to USD 5.5 million received from from Orphinic Scientific.

As part of the investment, and with the help of B2RLaw, Ambulero and Orphinic formed a Polish subsidiary (Ambulero Sp. z o.o.) that will lead clinical testing of a novel gene therapy for a serious vascular disease in Europe. The disease is rare in the US but more common in certain parts of Central and Eastern Europe.

Ambulero is a biotechnology company dedicated to advancing a platform of cell and gene therapies to treat serious vascular diseases. The company is a 2019 spin-out of the University of Miami co-founded by Robert L. Buchanan, Randy Berholtz, Omaida C. Velazquez and Jun Zhao-Liu. It holds an exclusive license from the University of Miami to develop and commercialize research from the laboratories of Drs. Omaida C. Velazquez and Jun Zhao-Liu.

With offices in Palo Alto, California and Warsaw, Poland, Orphinic Scientific is an innovative drug development and investment company focused on mid-market opportunities and orphan drugs in late preclinical research and Phase 1 or 2.

B2RLaw’s team was led by Partner Szymon Syp and included Senior Associate Iga Wojtczak – Opala and Junior Associate Jakub Niemiec.

Szymon Syp advises, “We congratulate Ambulero and Orphinic Scientific on this transaction. Ambulero’s important work means that people that suffer from serious vascular disease (which at best, causes severe discomfort and at worst, can result in death) can live in comfort with the knowledge that innovative treatment is on the horizon. We wish Ambulero the best of luck on its future clinical testing”.

View more resources

Catch up on the very latest B2RLAW
announcements and news here.

04/03/2021

B2RLaw advises PE fund Pinova Capital on the acquisition of software company Raynet GmbH

B2RLaw has advised PE fund Pinova Capital on the Polish aspects of its acquisition of a majority stake of German […]

MORE
02/03/2021

B2RLaw advises Oben Group on its acquisition of plastic packaging group, Poligal

B2RLaw has advised Oben Group on its acquisition of Poligal Group. The acquisition includes BOPP and CPP production plants in […]

MORE
23/02/2021

B2RLaw advises Nuveen Real Estate and Value One on their entry to the Polish student housing market

B2RLaw is advising Eagle JVCo on its acquisition of a portfolio of purpose-built student housing with around 800 beds including […]

MORE
22/02/2021

B2RLaw – No.1 for Venture Capital in CEE in 2020 according to PitchBook

In its first year, B2RLaw has been ranked as the No.1 most active law firm for venture capital in Central […]

MORE
11/02/2021

B2RLaw advises fintech company SMEO on over PLN 21 million VC financing round

B2RLaw has advised FinTech company SMEO on a transaction involving capital injection into the company from international VC fund Finch […]

MORE
05/02/2021

B2RLaw advises on PLN 260 million Krakow residential project

B2RLaw Jankowski Stroiński Zięba & Partners has advised an international real estate developer on the acquisition of a residential project […]

MORE

Get in touch

Not sure who to contact? Let us help you find the right lawyer.

This site uses cookies to improve your experience More information.

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close